#Amgen's fast-growing cancer #immunotherapy #Imdelltra could move into the first-line setting in #smallcelllungcancer (SCLC), after delivering as a #dualregimen with AstraZeneca's Imfinzi in the DeLLphi-305 study.

pharmaphorum.com/news/amgens-...